BHVN - Biohaven Pharmaceutical Holding Company Ltd.
| Previous Close | 35.74 |
| Open | 35.74 |
| Bid | 16.92 x 800 |
| Ask | 48.00 x 900 |
| Day's Range | 34.78 - 36.30 |
| 52 Week Range | 16.50 - 44.28 |
| Volume | 532,610 |
| Avg. Volume | 261,516 |
| Market Cap | 1.408B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.26 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.01 |
- GlobeNewswire•10 days ago
Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek — Fundamental Analysis, Key Performance Indications
NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•11 days ago
Biohaven Acquires Option To License Biologic Investigational Agent For Inflammatory And Autoimmune Diseases From The University of Connecticut
NEW HAVEN, Conn., Oct. 9, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announced today that it signed an exclusive, worldwide option and license agreement with the University of Connecticut for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein (MT). Extracellular MT has been implicated in the pathogenesis of autoimmune and inflammatory diseases. Under this agreement, Biohaven has the option to acquire an exclusive, worldwide license to UC1MT and its underlying patents to develop and commercialize throughout the world in all human indications.
- PR Newswire•last month
Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine
NEW HAVEN, Conn., Sept. 12, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the safety and tolerability of BHV-3500, the first small molecule calcitonin gene-related peptide (CGRP) receptor antagonist to be advanced into the clinic in an intranasal formulation. BHV-3500 is the second of Biohaven's CGRP-targeting compounds to reach this developmental milestone. Biohaven's multiple CGRP product candidates, including rimegepant, and formulations including oral tablet, Zydis® (Catalent) rapid dissolving tablet and intranasal delivery are designed to meet patients needs for both acute treatment and prevention of migraine.
- PR Newswire•last month
Biohaven Appoints Bob Repella to Board of Directors
NEW HAVEN, Conn., Sept. 12, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) today announced the appointment of Robert (Bob) Repella to its Board of Directors. Mr. Repella has extensive experience in the pharmaceutical industry, having held executive management roles at a number of companies including Wyeth Pharmaceuticals, Inc., Vanda Pharmaceuticals, Inc., Cephalon, Inc. and CSL Behring, Inc.. Earlier in his career, he held commercial positions at Eli Lilly & Company, Merck & Company, Inc. and Johnson & Johnson. Mr. Repella holds a Bachelor's Degree in pharmacy from Rutgers University and a Master of Business Administration in marketing from Temple University.
- PR Newswire•last month
Biohaven Presents at Migraine Trust International Symposium and Highlights Positive Results from Study 301 and Study 302 of Rimegepant, an Oral CGRP Receptor Antagonist, in the Acute Treatment of Migraine
NEW HAVEN, Conn., Sept. 6, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is presenting data from two randomized, pivotal Phase 3 clinical trials of rimegepant, a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, and a Phase 1 study of rimegepant ODT at the 17th Biennial Migraine Trust International Symposium (MTIS). "The data from these two pivotal Phase 3 trials show the potential of rimegepant as a much needed, new option for the acute treatment of migraine," said Richard B. Lipton, M.D., Professor and Vice Chair of Neurology at the Albert Einstein College of Medicine and Montefiore Health System, Director of the Montefiore Headache Center, and Chair of Biohaven's CGRP Scientific Advisory Board.
- Benzinga•last month
The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Biotech Stocks Hitting 52-week highs on Sept. 4) Aptinyx Inc (NASDAQ: APTX ) Becton Dickinson and Co ...
- PR Newswire•last month
Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy
NEW HAVEN, Conn. and NEW YORK, Sept. 5, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announced today that it entered into an exclusive, worldwide license agreement, through its subsidiary Biohaven Therapeutics Ltd., with AstraZeneca AB for the development and commercialization rights to AZD3241, an oral myeloperoxidase (MPO) inhibitor that AstraZeneca progressed through Phase 2 clinical trials. Biohaven plans to conduct a Phase 3 clinical trial of this product candidate for the treatment of multiple system atrophy (MSA) – a rare, rapidly progressive and fatal neurogenerative disease with no cure or effective treatments.
- Benzinga•2 months ago
The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 15) Inspire Medical Systems Inc (NYSE: INSP ) Merck & Co., Inc. ...
- PR Newswire•2 months ago
Biohaven Pharmaceuticals Reports Second Quarter 2018 Financial And Recent Business Results
- Announced $150 million transaction with Royalty Pharma which supports Biohaven's NDA filing activities for the oral CGRP antagonist program and to fund the Company's portfolio into the fourth quarter ...
- GlobeNewswire•3 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Protagonist Therapeutics, HD Supply, BIOHAVEN PHARM, Big Lots, Clean Energy Fuels, and H&E Equipment Services — New Research Emphasizes Economic Growth
NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Protagonist ...
- PR Newswire•3 months ago
First Patient Enrolled In Biohaven's Phase 2/3 Mild-To-Moderate Alzheimer's Clinical Trial
NEW HAVEN, Conn., Aug. 1, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company") announced today that it has enrolled the first patient in a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator for the treatment of mild-to-moderate Alzheimer's disease (AD). The trial is a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of trigriluzole in patients diagnosed with AD of mild-to-moderate severity (Mini-Mental State Examination scores of 14-24 at screening), and is being conducted in collaboration with the Alzheimer's Disease Cooperative Study (ADCS) at sites throughout the U.S.
- ACCESSWIRE•3 months ago
Free Stock Performance Review on Biogen and Three Additional Biotech Stocks
This morning, WallStEquities.com observes BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), Biogen Inc. (NASDAQ: BIIB), and Cerus Corp. (NASDAQ: CERS). The Biotechnology industry consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development.
- PR Newswire•3 months ago
Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease
NEW HAVEN, Conn., July 24, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company") announced today that it initiated a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator, in patients with mild-to-moderate Alzheimer's disease (AD). The initiation of this trial follows Biohaven's filing of an investigational new drug application (IND) for trigriluzole in AD and receipt from FDA of authorization to proceed with clinical investigation in this indication.
- TheStreet.com•4 months ago
Biohaven Pharma's New Migraine Drug Shows Promise in Late-Stage Test Results
previewed some promising test results from its new migraine drug, but shares have fallen almost 5% since Monday as the company has been affected by the recent decline in the biotech sector overall. has dropped 5.9% since June 20, and Biohaven's performance has been in line with that trend. "There's tremendous opportunity from a fundamental perspective," Folkes said.
- ACCESSWIRE•4 months ago
Free Technical Reports on Cerus and Three Additional Biotech Equities
Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), and Cerus Corp. (NASDAQ: CERS).
- PR Newswire•4 months ago
Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting
NEW HAVEN, Conn., June 28, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is presenting expanded data from two randomized, pivotal Phase 3 clinical trials of rimegepant, Biohaven's small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, on Saturday, June 30, 2018 at the American Headache Society (AHS) Annual Scientific Meeting 2018.
- ACCESSWIRE•4 months ago
Blog Exposure - Biohaven Signs Royalty Funding and Stock Purchase Agreements with Royalty Pharma
LONDON, UK / ACCESSWIRE / June 21, 2018 / If you want access to our free research report on Biohaven Pharma Holding Co. Ltd (BHVN) ("Biohaven"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BHVN as the Company's latest news hit the wire. On June 19, 2018, the Company announced that it has sold tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000), or BHV-3500, and certain derivative compounds thereof to Royalty Pharma for $100 million. Active-Investors.com is currently working on the research report for Myovant Sciences Ltd (MYOV), which also belongs to the Healthcare sector as the Company Biohaven Pharma Holding.
- Simply Wall St.•4 months ago
Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) Is Expected To Breakeven
Biohaven Pharmaceutical Holding Company Ltd’s (NYSE:BHVN): Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. With the latest financial yearRead More...
- PR Newswire•4 months ago
Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million
NEW HAVEN, Conn. and NEW YORK, June 18, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company") and Royalty Pharma announced today that Biohaven has sold tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000) or BHV-3500 and certain derivative compounds thereof to Royalty Pharma for $100 million. Royalty Pharma has also agreed to purchase $50.0 million in common shares of Biohaven, at a price of $45.00 per share, representing an approximately 19% premium over the 15-day volume-weighted average price through June 15, 2018.
- PR Newswire•4 months ago
Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region
NEW HAVEN, Conn., June 13, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, today announced that Ernst & Young (EY) named Biohaven CEO Vlad Coric as the Entrepreneur Of The Year® 2018 Award winner in the Health Care category in the New York region. The awards program recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities.
- PR Newswire•5 months ago
Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor Antagonist, During Four Late-Breaking Sessions at American Headache Society (AHS) Annual Scientific Meeting 2018
Presentations include clinically meaningful, comprehensive and durable benefits observed in two pivotal Phase 3 clinical trials of rimegepant for the acute treatment of migraine NEW HAVEN, Conn. , June ...
- Simply Wall St.•5 months ago
What Do Analysts Think About Biohaven Pharmaceutical Holding Company Ltd’s (NYSE:BHVN) Earnings Trend?
In December 2017, Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) released its latest earnings announcement, which signalled that losses became smaller relative to the prrior year’s level as a result ofRead More...
- PR Newswire•5 months ago
Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results
-- Successful Achievement of Registrational Co-Primary Endpoints and Key Secondary Endpoints in Two Pivotal Phase 3 Trials with Rimegepant (Oral CGRP Receptor Antagonist) for the Acute Treatment of Migraine, ...
- ACCESSWIRE•5 months ago
Our Free Research Report on Biogen and More Biotech Stocks
This Wednesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: AveXis Inc. (NASDAQ: AVXS), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd, (NYSE: BHVN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN): All you have to do is sign up today for this free limited time offer by clicking the link below. On Tuesday, shares in Bannockburn, Illinois headquartered AveXis Inc. recorded a trading volume of 941,320 shares, which was above their three months average volume of 884.73 thousand shares. The Company's shares have gained 88.91% over the previous three months and 181.89% in the past twelve months.
- PR Newswire•5 months ago
Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)
NEW HAVEN, Conn., May 9, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) today announced that it has established an expanded access program (EAP) with sublingual BHV-0223, an investigational drug candidate, for patients with amyotrophic lateral sclerosis (ALS). Through this program, physicians may be able to obtain BHV-0223 for their eligible patients with ALS at no cost. BHV-0223 is a sublingual and lower dose formulation of riluzole which employs the Zydis® orally dissolving tablet technology and does not require swallowing tablets or additional fluids.
